// App-Quantinova.ai

P-26 : RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma

Researchers

Presenter

  • R. Xu

Principal Investigators

  • T. Arkenau

  • Y. Bang

  • C. Denlinger

  • K. Kato

  • J. Tabernero

  • J. Wang

  • J. Li

  • H. Castro

  • M. Moehler

Medical Centers

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • Sarah Cannon Research Institute, London, United Kingdom

  • Seoul National University College of Medicine, Seoul, Korea

  • Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

  • National Cancer Center Hospital, Tokyo, Japan

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • BeiGene (Beijing) Co., Ltd., Beijing, China

  • BeiGene USA, Inc,San Mateo,United States

  • Johannes-Gutenberg Universitat Mainz, Mainz, Germany

Locations

  • China

  • United Kingdom

  • Republic of South Korea

  • United States

  • Japan

  • Spain

  • Germany

Companies

  • BeiGene (Beijing) Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Gastric Cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Capecitabine and oxaliplatin

  • Adrucil injection

  • Fluorouracil

  • Tislelizumab

  • Capecitabine

  • Oxaliplatin

  • Cisplatin

  • SP263

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved